REporting recommendations for tumor MARKer prognostic studies (REMARK). - Wikidata - wikimedia - TriplyDB

REporting recommendations for tumor MARKer prognostic studies (REMARK).

REporting recommendations for tumor MARKer prognostic studies (REMARK).

http://www.wikidata.org/entity/Q44579323

about

CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration.Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer -what has gone wrong? A blueprint for the way forward in biomarker studies Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration A comprehensive overview of targeted therapy in metastatic renal cell carcinoma C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review Prognostic Impact of Autophagy Biomarkers for Cutaneous Melanoma Serum Metabolomics Reveals Serotonin as a Predictor of Severe Dengue in the Early Phase of Dengue Fever Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases DNA methylation: potential biomarker in Hepatocellular Carcinoma.Prognostic value of long non-coding RNA CCAT1 expression in patients with cancer: A meta-analysis Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections.Strengthening the reporting of Genetic RIsk Prediction Studies: the GRIPS Statement.Urokinase plasminogen activator receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1) are potential predictive biomarkers in early stage oral squamous cell carcinomas (OSCC)E2F1-regulated long non-coding RNA RAD51-AS1 promotes cell cycle progression, inhibits apoptosis and predicts poor prognosis in epithelial ovarian cancer Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management.BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses.Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer.Prognostic value of survivin in patients with non-small cell lung carcinoma: a systematic review with meta-analysis A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.Altered expression of the miRNA processing endoribonuclease Dicer has prognostic significance in human cancers.Calpain system protein expression in carcinomas of the pancreas, bile duct and ampulla.An attempt at a molecular prediction of metastasis in patients with primary cutaneous melanoma.MTHFR Glu429Ala and ERCC5 His46His polymorphisms are associated with prognosis in colorectal cancer patients: analysis of two independent cohorts from Newfoundland.A comprehensive analysis of Aurora A; transcript levels are the most reliable in association with proliferation and prognosis in breast cancer.Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays.RiGoR: reporting guidelines to address common sources of bias in risk model development.Circulating serum trefoil factor 3 (TFF3) is dramatically increased in chronic kidney disease.High MACC1 expression in combination with mutated KRAS G13 indicates poor survival of colorectal cancer patients.Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy A Cohort Study of p53 Mutations and Protein Accumulation in Benign Breast Tissue and Subsequent Breast Cancer Risk.Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy.Cancer immunology--analysis of host and tumor factors for personalized medicine.PASSIM--an open source software system for managing information in biomedical studies Co-Expression of TWIST1 and ZEB2 in Oral Squamous Cell Carcinoma Is Associated with Poor Survival The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer.Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection.

P2860

Q21195205-CB005711-F007-48C5-876B-9540EA16B61C Q24289354-DAB031C8-5912-45E2-ADC1-E547636E2399 Q24289356-93B35F94-BD15-4898-A921-C035CB4F1F1E Q24289476-ADD0B95E-5657-4117-A5C1-9CDFA7EA8030 Q24606852-2D069900-717F-44C3-B813-739A9D8F9E4A Q26771557-E0458835-63AE-4456-89DB-4ACCD33563F4 Q28067140-BB20623A-E5B1-43FB-BA4D-70F244EE352C Q28551236-568D3312-F62F-4B7A-BF5D-85411B3EC45E Q30503693-04C70030-39F5-4C18-8AE7-D901AD77E90C Q33617129-1EBE88B3-44C6-4166-BB8D-CA2B433C357E Q33778789-E8D59FC8-8725-4B7F-8EF9-3BFCD03CACC8 Q33843751-49829ECB-610A-466D-A3A8-FFB3F511C6A8 Q33851304-8E988CAB-4ED5-428E-9B59-AEC37C9DE97A Q33856467-7B881E22-29A6-42C1-9E7F-139F62E8E26C Q33860997-A03592E0-3864-456D-90A2-3A2F3E7329FB Q33905899-80B5DEEB-0BD7-433E-B01C-3A841FE88001 Q33920189-4D5A686A-B1D1-48DF-9025-21031AD5DED8 Q34008793-F0D8B832-A78F-438D-84EE-3054AE71CB5B Q34066371-0F1CFFA3-E1D3-4C53-B041-FAE6FC16BC65 Q34212175-C36D6144-F07B-44A5-8AD4-97B6F021197F Q34268261-2F4190C3-10DF-4DE1-B0C8-ECEACA3E9B6E Q34319010-F2D01947-71BB-4438-BD0F-411E82CC8393 Q34472484-45151809-669A-4866-A22D-78E9365CDCD0 Q34482829-DC56981B-33BA-48D2-A283-3FC6695E21F4 Q34692175-1BC64D98-8D4F-47A5-8BEA-7ACF635F9934 Q34694095-3759A08F-2541-4801-BA58-718F26FC5880 Q34916073-83AB2CEC-B36D-4ED3-A910-2297656A30CD Q34996501-6A654AA8-6338-47AB-8AB2-25B9A810C515 Q35033342-75AD6638-24B7-4425-A0AD-F168F6195A0F Q35055099-72072DF5-792A-40CE-891E-0E192181501C Q35104374-5A85CEA3-C724-4C1C-8854-3539A5551887 Q35149589-384154EE-60D3-4D61-B446-FB6F61069696 Q35176681-A48DDC8A-62EB-42AC-AB1C-CF1699F07027 Q35506253-986169AE-5715-41B7-B375-EBA67FC40F6C Q35583180-662515E1-44F8-44F1-AD5B-6D120FC4C008 Q35648652-852AAFAF-0094-4A64-902A-8A64F24A2E68 Q35716304-D152A7B5-99AF-43A4-A83B-90D3489E37C4 Q35858991-1DD860E6-0698-4116-988C-091B804E075D Q35904441-ABABFD83-941B-452B-B927-FEF66E56F6F7 Q35926074-532B2B58-CC1B-493A-90CB-92D95AA6933F

P2860

REporting recommendations for tumor MARKer prognostic studies (REMARK).

http://www.wikidata.org/entity/Q44579323

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

REporting recommendations for tumor MARKer prognostic studies (REMARK).

@en

type

label

REporting recommendations for tumor MARKer prognostic studies (REMARK).

@en

prefLabel

REporting recommendations for tumor MARKer prognostic studies (REMARK).

@en

P1433

Q44579323-3B84AC23-EC43-4086-9636-DDCD5485E995

P1476

Q44579323-680D018B-394E-4A4D-B56D-A4F348024997

P2093

Q44579323-0403EFD7-BB1D-4DAA-9AF0-D002B45DDCBD

Q44579323-733DBA9A-F76F-435F-9EE5-262FA8B7D713

Q44579323-C31A6FE1-941F-406A-9AEE-5AC0CE27CC9D

Q44579323-DB94A679-9D5F-45D4-9439-015F91F05B8A

Q44579323-EA4B4568-624C-4780-88A2-9BF9345DD958

Q44579323-FC76740C-B6C8-4F88-8219-EC1AC859F33A

P2860

Q44579323-03FFCD74-ED9B-4296-9762-45E142F39672

Q44579323-0857F80D-CC5E-4455-867E-546E89A36B6C

Q44579323-0F806BA1-1140-4410-B288-61CF6C320090

Q44579323-50A526C9-6420-48B7-ADF7-A23A26E11AE6

Q44579323-56295FC0-B8F1-4B62-9BFD-4A20FEAD759C

Q44579323-59170483-E800-4A64-BF68-B4472A300080

Q44579323-63B51411-AFD9-4FD3-A1FD-49D2278B2318

Q44579323-80777E35-A4B7-49EF-A09C-71168AF41F4E

Q44579323-819166F7-384E-47EB-9605-B8C86B9DC7B0

Q44579323-87768A12-FF57-4F0B-A03E-5903F68D8D36

P2888

Q44579323-A4904CBC-BF3B-436E-9A07-BC6637592420

P304

Q44579323-23B2FB3B-305A-483F-A9C6-34CA1EDCE404

P31

Q44579323-178866AE-28B0-441F-AAAF-D7D6DF9A2B66

P356

Q44579323-12CBB1AA-D03B-477B-9819-64D5B1C5A54A

P407

Q44579323-73A3533D-7D7F-4128-B563-9B3C4A67C06E

P433

Q44579323-50CD9D68-2575-4A44-B5C0-D6256EB3B764

P478

Q44579323-E2418CBE-5868-43FD-BBE7-B6E9FD6F6E4F

P50

Q44579323-8E35C7DE-4C11-431A-8951-7A4ABF75A97D

P577

Q44579323-A174CFBB-BF00-4654-A797-AC19BAA8288B

P6179

Q44579323-B4B1D061-74AB-40D6-8553-A44F1A5AE6BF

P698

Q44579323-5e4c79a1-bfe0-4edf-b0bf-77acefa10863

Q44579323-E48D0734-3375-42FA-8A2F-11F459FE4710

P356

P1433

Nature Reviews Urology

P1476

REporting recommendations for tumor MARKer prognostic studies (REMARK).

@en

P2093

Gary M Clark

http://www.w3.org/2001/XMLSchema#string

Lisa M McShane

http://www.w3.org/2001/XMLSchema#string

Massimo Gion

http://www.w3.org/2001/XMLSchema#string

Sheila E Taube

http://www.w3.org/2001/XMLSchema#string

Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics

http://www.w3.org/2001/XMLSchema#string

Willi Sauerbrei

http://www.w3.org/2001/XMLSchema#string

P2860

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

The revised CONSORT statement for reporting randomized trials: explanation and elaboration

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

Potential for selection bias with tumor tissue retrieval in molecular epidemiology studies.

Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines

Methodological challenges in the evaluation of prognostic factors in breast cancer.

Predicting the future: a critical appraisal of cancer prognosis studies.

Systematic reviews of evaluations of prognostic variables.

Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years.

P2888

P304

416-422

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCPONC0252

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Douglas G. Altman

P577

2005-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1043056465

http://www.w3.org/2001/XMLSchema#string

P698

16482653

http://www.w3.org/2001/XMLSchema#string